

Remarks

Claims 2, 4, 12, and 15-21 were pending in the subject application, of which claims 16-21 were currently under examination. By this Amendment, claims 2, 4, 12, 15, 18, and 21 have been canceled without prejudice. Accordingly, claims 16, 17, 19, and 20 are currently before the Examiner for her consideration, and favorable consideration of the pending claims is respectfully requested.

The Office Action of July 30, 2002 indicated that claims 16, 17, 19, and 20 were allowable. Claims 18 and 21 were rejected under 35 U.S.C. § 112, first paragraph. Applicants have cancelled claims 2, 4, 12, 15, 18, and 21 solely for the purpose of expediting the issuance of allowable claims 16, 17, 19, and 20. However, Applicants reserve the right to pursue the subject matter of claims 2, 4, 12, 15, 18, and 21 in related applications.

The Examiner indicated that the current application lacked the current status of the non-provisional parent application, U.S. Serial No. 09/191,997. This issue has been obviated by the present amendment to the specification.

In the Office Action of July 30, 2002, the filing date of the parent application, 09/191,997, filed November 13, 1998, was considered as the priority date. For purpose of establishing the effective priority date, Applicants were requested to identify which provisional, if any, contain the protein and encoding nucleic acid sequences and to identify what the SEQ ID NOS. are in those applications that correspond to the instant invention. Applicants respectfully respond that the protein of SEQ ID NO:92, which is disclosed in U.S. Provisional Patent Application Serial No. 60/066,677, filed November 13, 1997, and in U.S. Provisional Patent Application Serial No. 60/069,957, filed December 17, 1997, corresponds to the protein of SEQ ID NO:186 of the present application. The protein of SEQ ID NO:92 is encoded by the cDNA of SEQ ID NO:45 in U.S. Provisional Patent Application Serial Nos. 60/066,677 and 60/069,957.


The Office Action has requested copies of the references cited in the IDS filed May 20, 2002 that were not submitted with parent application 09/191,997. Paper copies of those references are enclosed herewith and, for the convenience of the Examiner, a Form 1449 is provided herewith for initialing in the consideration of these references.

Applicants also request entry of the attached Communication with Revocation of Power of Attorney and New Power of Attorney transferring power to the undersigned.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants respectfully submit that the present application is fully in condition for allowance and such action is earnestly solicited. If any questions remain, the Examiner is invited to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 NW 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/jaj

Attachments: Marked-Up Version of Amended Paragraph of Specification
Information Disclosure Statement, with attachments
Communication with attachments regarding Power of Attorney

#18
DmJ
124-1

I hereby certify that this correspondence is being deposited on January 22, 2003, with the United Parcel Service for Overnight Delivery on January 23, 2003, to Examiner Eileen B. O'Hara, U.S. Patent and Trademark Office, Crystal Mall I, 1911 Clark Street, Seventh Floor, Arlington, VA 22202.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1646
Patent Application
Docket No. G-031US03CIP
Serial No. 09/663,600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Eileen B. O'Hara
Art Unit : 1646
Applicant(s) : Jean-Baptiste Dumas Milne Edwards, et al.
Serial No. : 09/663,600
Filed : September 15, 2000
Conf. No. : 2172
For : Extended cDNAs for Secreted Proteins

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

RECEIVED
PTO/PRM
JAN 24 2003
03 19117:19
663600

24/2003 DTHOMAS 0000002 190065 09663600
C:1806 Sir.
180.00 CH


In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/dkt

Attachments: Form PTO/SB/08A & B (1 pages)
Copies of references cited